Scott Collins's Colleagues at QED Therapeutics
Scott Collins's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Scott Collins's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Scott Collins
Scott Collins currently works for QED Therapeutics.
Scott Collins's role at QED Therapeutics is Vice President - Market Access.
Scott Collins's email address is ***@qedtx.com. To view Scott Collins's full email address, please signup to ConnectPlex.
Scott Collins works in the Biotechnology industry.
Scott Collins's colleagues at QED Therapeutics are Dawn Hill, Mike Monteith, Stacie Shepherd, Todd Bobick, Mar Reyes, Lihua Zhang, Brian Eater and others.
Scott Collins's phone number is 650-231-4088